BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 24937264)

  • 21. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
    de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
    Lieberman DA; Weiss DG;
    N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal immunochemical testing results and characteristics of colonic lesions.
    van Doorn SC; Stegeman I; Stroobants AK; Mundt MW; de Wijkerslooth TR; Fockens P; Kuipers EJ; Bossuyt PM; Dekker E
    Endoscopy; 2015 Nov; 47(11):1011-7. PubMed ID: 26126163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms.
    Chiu HM; Ching JY; Wu KC; Rerknimitr R; Li J; Wu DC; Goh KL; Matsuda T; Kim HS; Leong R; Yeoh KG; Chong VH; Sollano JD; Ahmed F; Menon J; Sung JJ;
    Gastroenterology; 2016 Mar; 150(3):617-625.e3. PubMed ID: 26627608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
    Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
    J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
    Haug U; Hundt S; Brenner H
    Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer.
    Duran-Sanchon S; Moreno L; Gómez-Matas J; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Serradesanferm A; Pozo À; Grau J; Pellisé M; Gironella M; Castells A
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):323-330.e1. PubMed ID: 32113893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance.
    Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Joo KR; Lee JI
    J Clin Gastroenterol; 2017 Oct; 51(9):825-830. PubMed ID: 27824639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
    Brenner H; Tao S
    Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualized colorectal cancer screening based on the clinical risk factors: beyond family history of colorectal cancer.
    Park CH; Kim NH; Park JH; Park DI; Sohn CI; Jung YS
    Gastrointest Endosc; 2018 Jul; 88(1):128-135. PubMed ID: 29510145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round.
    Digby J; Fraser CG; Carey FA; Diament RH; Balsitis M; Steele RJ
    J Med Screen; 2017 Jun; 24(2):62-68. PubMed ID: 27370211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening.
    van Roon AH; Goede SL; van Ballegooijen M; van Vuuren AJ; Looman CW; Biermann K; Reijerink JC; Mannetje H'; van der Togt AC; Habbema JD; van Leerdam ME; Kuipers EJ
    Gut; 2013 Mar; 62(3):409-15. PubMed ID: 22387523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants.
    Aniwan S; Rerknimitr R; Kongkam P; Wisedopas N; Ponuthai Y; Chaithongrat S; Kullavanijaya P
    Gastrointest Endosc; 2015 Mar; 81(3):719-27. PubMed ID: 25708760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing and Risk Factors for a Positive Fecal Immunochemical Test in Subsequent Screening for Colorectal Neoplasms.
    Chiang TH; Lee YC; Liao WC; Chung JH; Chiu HM; Tu CH; Chen SC; Wu MS
    PLoS One; 2015; 10(9):e0136890. PubMed ID: 26332318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program.
    Chiu SY; Chuang SL; Chen SL; Yen AM; Fann JC; Chang DC; Lee YC; Wu MS; Chou CK; Hsu WF; Chiou ST; Chiu HM
    Gut; 2017 Feb; 66(2):293-300. PubMed ID: 26515543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
    Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
    Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.